3

PRIMARY DOCUMENT

Company: Viridian Therapeutics, Inc.\DE
Filed: July 27, 2021
Period of Report: July 26, 2021
Accession Number: 0000950123-21-009252

View Document ↗ View on SEC.gov ↗